Yellow fever vaccine (YFV) has been used for over 70 years in endemic areas. It is produced from 17D attenuated viral strain and is rarely associated with serious adverse events (SAE), such as anaphylaxis and YFV-associated neurotropic and viscerotropic diseases.
We report the case of a patient with AML who started chemotherapy just 7 days after yellow fever (YF) vaccination. 17D viral load was monitored by RT-PCR, as well as clinical and laboratory abnormalities. Levels of neutralizing Abs (NA) against 17D were also quantified.
The titration of NA against YF was performed at Fiocruz, Rio de Janeiro, using a Plaque Reduction Neutralization Test 8 in serial twofold dilutions starting at 1:5, in 50 mL aliquots of heatinactivated (56 1C for 30 min) serum, in 96-well tissue culture plates. 9 A positive in house monkey serum sample with YF Ab content calibrated by a WHO International Reference Preparation, with 1115 mIU/mL was the reference for each set of tests, 10 and was repeated every 10 samples. After incubation at room temperature for 1 h, a suspension of Vero cells was added and the plates were incubated for 3 h. The medium was then discarded and the cells overlaid with 100 mL of medium containing carboxymethylcellulose. After incubation for 7 days at 37 1C in 5% CO 2 , cell monolayers were fixed with 10% formalin, stained with 0.04% crystal violet and plaques counted. The mean Ab content at the 50% end point of the standard was calculated through linear regression. The mean titre of the standard sera determined the levels of protection in each sample.
Total RNA was extracted from 140 mL of plasma using QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany) and eluted in 60 mL of elution buffer. cDNA was obtained through a reverse transcriptase reaction using 10 mL of the extracted RNA, 300 ng of random primer (Amersham Biosciences, Piscataway, NJ, USA); 10 U/mL of Super Script TM II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a buffer solution with 0.25 U/mL of ribonuclease inhibitor (Invitrogen) and 0.5 mM deoxyribonucleotide triphosphates (Invitrogen), at final volume of 20 mL. The reaction was incubated at 45 1C for 90 min. Five microlitres of cDNA was added to 20 mL of TaqMan Master Mix (Applied Biosystems, Foster City, CA, USA) and was amplified by RT-PCR using the following primers and probe: (YF-NS5_F) 5
0 -GCACGG ATGTAACAGACTGAAGA-3 0 ; (YF-NS5_R) 5 0 -CCAGGCCGAACCTGTC AT-3 0 and (YF-NS5Probe) 5 0 -FAM-CGACTGTGTGGTCCGGCCCATC-3 0 -TAMRA. 11 The product was amplified using optical detection system layout of
An asymptomatic 39 year-old man was diagnosed with AML after routine blood test. BM aspiration demonstrated 76% blasts, urging chemotherapy initiation. He had been vaccinated against YF for the first time 7 days before chemotherapy was started. Detailed clinical and laboratory follow up for possible YFVassociated AE was performed, and 17D viral load was monitored by RT-PCR, daily for the first 19 days after vaccination (Table 1) . He remained clinically stable, without any neurological or hepatic abnormalities that could resemble YFV-associated neurotropic or viscerotropic disease. 17D viral load, as measured by RT-PCR, decreased progressively from the first measurement, with undetectable levels on day 16. NA against 17D were measured on day 28 after vaccination, and surprisingly indicated protective levels. This is an unusual case of YF vaccination followed by chemotherapy-induced severe immunosuppression. The 17D viremia was documented for 15 days after vaccination, and was not associated with detectable AE. Surprisingly, protective NA titers were detected 1 month after the vaccine, indicating memory B lymphocytes may have been preserved despite ablative BM suppression.
The use of 17D in immunosuppressed patients is a common concern in clinical practice and several points remain unknown. In a recent review, 17D AE in vulnerable populations of children, pregnant women, older persons, HIV positive patients and in individuals taking immunosuppressive medications were described. Although SAE have been identified among older persons and breastfeeding mothers, no change in the current understanding of the risk of 17D SAE could be provided by this comprehensive review. 12 Several inconclusive reports described mutations in 17D that may be associated with SAE. [13] [14] [15] [16] However, a particular strain related to the lack of AE in an immunosuppressed individual has not been described. Host genetic susceptibilities may also have an important role in the development of YFV AE. In previous reports, cases of YFV AE have been associated with high and prolonged 17D viral load, abnormalities in innate immune response and genetic polymorphisms in chemokine receptor CCR5, and its ligand RANTES. 17, 18 Populations of immunosuppressed individuals are likely to increase worldwide, raising concern about the use of live attenuated vaccines and their possible AE. YFV zones have been expanding in recent years in several regions of South America, in order to prevent potential urban outbreaks of the disease. who live or travel to YF endemic zones, it is important to establish
